2-氨基-3-羟基丁酸甲酯盐酸盐

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-3-羟基丁酸甲酯盐酸盐
• 中文别名: DL-苏氨酸甲酯盐酸盐
• 英文名称: methyl 2-amino-3-hydroxybutanoate hydrochloride
• 英文别名: (D,L)-threonine methyl ester hydrochloride；threonine methyl ester hydrochloride；(3-hydroxy-1-methoxy-1-oxobutan-2-yl)azanium;chloride
• 化学式: C₅H₁₁NO₃*ClH
• mdl: MFCD00070400
• 分子量: 169.608
• InChiKey: OZSJLLVVZFTDEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.06
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  72.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氨基-3-羟基丁酸甲酯盐酸盐 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以96%的产率得到methyl N-acetyl-threoninate
  参考文献：
  名称：

  Torrini, Ines; Zecchini, Giampiero Pagani; Agrosi, Francesco, Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 1459 - 1463

  摘要：

  DOI：
• 作为产物：
  描述：

  3-羟基丁酸甲酯 在 N-碘代丁二酰亚胺 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 20.0h， 生成 2-氨基-3-羟基丁酸甲酯盐酸盐
  参考文献：
  名称：

  自由基介导的烷基亚氨酸分子内β-C（sp 3）–H酰胺化反应：1,2-氨基醇的合成

  摘要：

  报道了一种新的自由基介导的O-烷基三氯或芳基亚氨酸酯的分子内β-C（sp 3）-H酰胺化反应。从容易获得的酒精原料中可以有效地制备出各种恶唑啉。三氯恶唑啉产物可以在温和的条件下水解，得到有价值的1,2-氨基醇。该酰胺化反应具有广泛的底物范围和良好的官能团耐受性，并为醇的C（sp 3）-H官能化提供了强有力的手段。机理研究表明，亚胺基自由基，碘化和环化反应的1，5-HAT序列可能是有效的。

  DOI：

  10.1039/c7cc08897c

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2018006063A1

  公开（公告）日：2018-01-04

  Compositions and methods for the treatment of bacterial infections include compounds containing dimers of cyclic heptapeptides conjugated to one or more monosaccharide or oligosaccharide moieties. In particular, compounds can be used in the treatment of bacterial infections caused by Gram-negative bacteria.

  用于治疗细菌感染的组合物和方法包括含有环七肽二聚体与一个或多个单糖或寡糖基团结合的化合物。特别是，这些化合物可用于治疗由革兰氏阴性细菌引起的细菌感染。
• [EN] SYNTHESIS AND USE OF HETEROCYCLIC ANTIBACTERIAL AGENTS<br/>[FR] SYNTHÈSE ET UTILISATION D'AGENTS ANTIBACTÉRIENS HÉTÉROCYCLIQUES
  申请人：SCHERING CORP

  公开号：WO2009158369A1

  公开（公告）日：2009-12-30

  This invention relates to compounds of the following Formula (I); or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which is useful for the treatment of diseases or conditions mediated by LpxC.

  这项发明涉及以下式（I）的化合物；或其药学上可接受的盐、溶剂合物、酯或异构体，用于治疗由LpxC介导的疾病或症状。
• Dehydrodipeptide Hydrogelators Containing Naproxen <i>N</i>-Capped Tryptophan: Self-Assembly, Hydrogel Characterization, and Evaluation as Potential Drug Nanocarriers
  作者：Helena Vilaça、Ana C. L. Hortelão、Elisabete M. S. Castanheira、Maria-João R. P. Queiroz、Loic Hilliou、Ian W. Hamley、José A. Martins、Paula M. T. Ferreira

  DOI：10.1021/acs.biomac.5b01006

  日期：2015.11.9

  In this work, we introduce dipeptides containing tryptophan N-capped with the nonsteroidal anti-inflammatory drug naproxen and C-terminal dehydroamino acids, dehydrophenylalanine (ΔPhe), dehydroaminobutyric acid (ΔAbu), and dehydroalanine (ΔAla) as efficacious protease resistant hydrogelators. Optimized conditions for gel formation are reported. Transmission electron microscopy experiments revealed that the hydrogels consist of networks of micro/nanosized fibers formed by peptide self-assembly. Fluorescence and circular dichroism spectroscopy indicate that the self-assembly process is driven by stacking interactions of the aromatic groups. The naphthalene groups of the naproxen moieties are highly organized in the fibers through chiral stacking. Rheological experiments demonstrated that the most hydrophobic peptide (containing C-terminal ΔPhe) formed more elastic gels at lower critical gelation concentrations. This gel revealed irreversible breakup, while the C-terminal ΔAbu and ΔAla gels, although less elastic, exhibited structural recovery and partial healing of the elastic properties. A potential antitumor thieno[3,2-b]pyridine derivative was incorporated (noncovalently) into the gel formed by the hydrogelator containing C-terminal ΔPhe residue. Fluorescence and Förster resonance energy transfer measurements indicate that the drug is located in a hydrophobic environment, near/associated with the peptide fibers, establishing this type of hydrogel as a good drug-nanocarrier candidate.

  在这项工作中，我们介绍了含有色氨酸、N端以非甾体抗炎药萘普生封端、C端为脱水氨基酸（脱水苯丙氨酸（ΔPhe）、脱水氨基丁酸（ΔAbu）和脱水丙氨酸（ΔAla））的二肽，这些二肽作为有效的蛋白酶抵抗型水凝胶形成剂。我们报告了最佳凝胶化条件。透射电子显微镜实验揭示，水凝胶由通过肽自组装形成的微/纳米尺寸纤维网络组成。荧光光谱和圆二色光谱表明，自组装过程是由芳香族基团的堆积相互作用驱动的。萘普生部分的萘环在纤维中通过手性堆积高度有序。流变学实验证明，最疏水的肽（含C端ΔPhe）在较低的临界凝胶化浓度下形成了更具弹性的凝胶。这种凝胶显示出不可逆的破碎，而C端ΔAbu和ΔAla凝胶虽然弹性较差，但表现出结构恢复和部分弹性性能的愈合。将一种潜在的抗肿瘤噻吩并[3,2-b]吡啶衍生物（非共价地）掺入含C端ΔPhe残基的凝胶形成剂形成的水凝胶中。荧光和福斯特共振能量转移测量表明，药物位于疏水环境中，靠近/与肽纤维相连，这表明这种类型的水凝胶是一个良好的药物纳米载体候选者。
• [EN] OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS OXAZOLE ANTAGONISTES DES RÉCEPTEURS D'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015018029A1

  公开（公告）日：2015-02-12

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及氧唑化合物，其为促进睡眠的受体拮抗剂。本发明还涉及所述氧唑化合物在潜在治疗或预防涉及促进睡眠的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进睡眠的疾病中的用途。
• [EN] OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR D'OREXINE À BASE D'OXAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015020930A1

  公开（公告）日：2015-02-12

  The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及氧唑化合物，其为促进素受体的拮抗剂。本发明还涉及所述氧唑化合物在潜在的治疗或预防涉及促进素受体的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗涉及促进素受体的疾病中的用途。